Sign in

close

Registering for this site allows you to access your order status and history. Just fill in the fields below, and we’ll get a new account set up for you in no time. We will only ask you for information necessary to make the purchase process faster and easier.

Create an Account

Shopping cart

close
  • No products in the cart.
We have updated our Privacy Policy. Learn more here.
close

4-Day Meal Program

CHEMOLIEVE®


L-Nutra’s second FMD® is a 4-day meal program currently undergoing clinical testing at five different hospitals to evaluate whether it supports the body during chemotherapy and helps with decreasing side effects and recovery. Chemolieve® clinical trials are being conducted at the University of Southern California, Mayo Clinic, Leiden University, and the University of Genoa.

Chemolieve® is the first 4-day meal replacement based on proprietary dietary interventions to supply the body with important nutrients to reduce adverse side effects of chemotherapy.

Patients undergoing prolonged periods of fasting prior to, during and after chemotherapy, have reported reduction in a wide range of side effects. Because cancer patients are generally unable or unwilling to fast for prolonged periods of time, and since one or more cycles of fasting and chemotherapy may lead to additional malnourishment and nutritional deficiencies, L-Nutra developed a proprietary food (Chemolieve®) to support chemotherapy treatment by selectively nourishing normal cells.

USC Norris Cancer Center


A phase I human clinical trial on the role of 24-72 hours of fasting on chemotherapy side effects at the USC Norris Cancer Center has also been completed and indicates that up to 72 hours of fasting in combination with certain chemotherapy drugs is safe. A clinical trial on Chemolieve®, and chemotherapy side effects and efficacy began at the USC Norris Cancer Center in early 2012.

Early human data from patients receiving dietary formulations equivalent to Chemolieve® strongly suggest that Chemolieve® will achieve the desired changes in the blood markers that are believed to be essential for maintaining normal human tissues and sensitization of certain cancers to chemotherapy.

Additional clinical studies on the efficacy of Chemolieve® have commenced at the University of Southern California (USC), the Angeles Clinic, the Mayo Clinic, Leiden University (Holland) and University of Genoa (Italy).

In animal studies Chemolieve® was shown to be effective in the protection against a variety of chemotherapy drugs including doxorubicin, cyclophosphamide, and cisplatin. Chemolieve® was also shown to sensitize multiple tumor cells, including breast cancer cells, to chemotherapy.

Scroll To TopScroll To Top